Extranodal Non-Hodgkin Lymphoma — Trials

Extranodal Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 18
Ph III recruiting: 1
Growth YoY: —
Industry share: 13%
Top sponsor: Ruijin Hospital
Termination share: 32.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (43)

clinicaltrialsPublishedShowing 51–52 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04526834	Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN)	active not recruiting	Phase 1	21	Tessa TherapeuticsINDUSTRY	1	Apr 20, 2023	clinicaltrials
NCT02859402	Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT)	recruiting	Phase 2	34	Keimyung University Dongsan Medical CenterOTHER	1